This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

XOVOLTIB® significantly improved dyspnoea and some pain symptoms compared with pemetrexed/cisplatin1

More patients (≥50%) on XOVOLTIB® experienced clinically meaningful improvements in pre-specified tumour symptoms (dyspnoea, pain and cough)1

XOVOLTIB® delayed time to worsening of clinically relevant symptoms versus pemetrexed/cisplatin1

LUX-Lung 3: Median TTD of symptoms. EORTC QoLQLQ-C30 and QLQ LC-13

  • Compared with chemotherapy, XOVOLTIB® delayed time to deterioration of cough (27 vs 8 months, P=0.006), dyspnoea (10.4 vs 2.9 months, P=0.013) and pain (4.2 vs 3.1 months, P=0.188), respectively2

XOVOLTIB® significantly improved QoL versus pemetrexed/cisplatin1

Global health status and functioning. EORTC QoLQLQ-C30 questionnaire scores longitudinal analysis

  • XOVOLTIB® had significantly better mean QoL scores over time for global health status/QoL, physical role, and cognitive functioning1

CI=confidence interval; EGFR M+=epidermal growth factor receptor mutation positive; EORTC=European Organisation for Research and Treatment of Cancer; QoL=quality of life; TTD=time to deterioration, the time from randomisation to first appearance of a score ≥10 points lower than the baseline score.

You may be interested in: 

Is this information compelling to you?

References

  1. Yang JC et al. J Clin Oncol. 2013;31(27):3342-3350.
  2. Wu YL et al. Poster presented at: ESMO Congress; Madrid, Spain; 26-30 September 2014.
  1. [1] Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.

  2. [2] Wu YL et al. Lancet Oncol. 2014;15(2):213-222.

  3. [3] Yang JC et al. Lancet Oncol. 2015;16(2):141-151.

  4. [4] Park K et al. Lancet Oncol. 2016;17(5):577-589.

  5. [5] Soria JC et al. Lancet Oncol. 2015;16(8):897-907.

  6. [6] Solca F et al. J Pharmacol Exp Ther. 2012;343(2):342-350.

  7. [7] Yang JC et al. J Clin Oncol. 2013;31(27):3342-3350.

  8. [8] Hirsch V et al. Poster #369 presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA; 3-7 June 2016.

  9. [9] Yang JCH et al. Ann Oncol. 2016;27(11):2103-2110.

  10. [10] Schuler M et al. J Thorac Oncol. 2016;11(3):380-390.

  11. [11] Paz-Arez L et al. Ann Oncol. 2017; 28(2):270-277

  12. [12] XOVOLTIB® Local pack insert version dated 21st July 2017

In case you come across any adverse events related to our products, please report it to PV team immediately.
Phone: +91 9819241697
Email: PV_local_India@boehringer-ingelheim.com

For any query on Boehringer Ingelheim India's product or therapy area, kindly contact
Phone: 1800227887
Email: medical.query.mum@boehringer-ingelheim.com

Back to top